Trade Sage Therapeutics, Inc. - SAGE CFD
Add to favourite- Summary
- Historical Data
- Events
- Income Statement
- Balance Sheet
- Cash Flow
- Ownership
Spread | 0.17 | ||||||||
Long position overnight fee
Long position overnight fee
Go to platform | -0.026207% | ||||||||
Short position overnight fee
Short position overnight fee
Go to platform | 0.003985% | ||||||||
Overnight fee time | 22:00 (UTC) | ||||||||
Min traded quantity | 1 | ||||||||
Currency | USD | ||||||||
Margin | 5% | ||||||||
Stock exchange | United States of America | ||||||||
Commission on trade | 0% |
*Information provided by Capital.com
SAGE Therapeutics Inc ESG Risk Ratings
‘C’ score indicates satisfactory relative ESG performance and moderate degree of transparency in reporting material ESG data publicly.
Prev. Close* | 19.94 |
Open* | 19.39 |
1-Year Change* | -50.35% |
Day's Range* | 19.39 - 20.05 |
52 wk Range | 16.52-59.99 |
Average Volume (10 days) | 945.50K |
Average Volume (3 months) | 23.51M |
Market Cap | 1.16B |
P/E Ratio | -100.00K |
Shares Outstanding | 59.97M |
Revenue | 11.35M |
EPS | -10.98 |
Dividend (Yield %) | N/A |
Beta | 1.11 |
Next Earnings Date | Feb 14, 2024 |
All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
Date | Close | Change | Change (%) | Open | High | Low |
---|---|---|---|---|---|---|
Dec 8, 2023 | 19.94 | -0.58 | -2.83% | 20.52 | 20.84 | 19.89 |
Dec 7, 2023 | 20.77 | 0.10 | 0.48% | 20.67 | 21.12 | 20.42 |
Dec 6, 2023 | 20.80 | 0.24 | 1.17% | 20.56 | 21.07 | 20.48 |
Dec 5, 2023 | 20.75 | 0.54 | 2.67% | 20.21 | 20.93 | 20.13 |
Dec 4, 2023 | 20.76 | 0.56 | 2.77% | 20.20 | 20.79 | 19.90 |
Dec 1, 2023 | 20.30 | 1.22 | 6.39% | 19.08 | 20.34 | 18.73 |
Nov 30, 2023 | 19.55 | -0.14 | -0.71% | 19.69 | 20.11 | 19.35 |
Nov 29, 2023 | 19.41 | 0.31 | 1.62% | 19.10 | 19.89 | 19.10 |
Nov 28, 2023 | 19.21 | 0.63 | 3.39% | 18.58 | 19.27 | 18.31 |
Nov 27, 2023 | 18.98 | -0.23 | -1.20% | 19.21 | 19.21 | 18.60 |
Nov 24, 2023 | 19.44 | 0.11 | 0.57% | 19.33 | 19.82 | 19.26 |
Nov 22, 2023 | 19.36 | 0.02 | 0.10% | 19.34 | 19.68 | 19.00 |
Nov 21, 2023 | 19.26 | 0.02 | 0.10% | 19.24 | 19.68 | 19.10 |
Nov 20, 2023 | 19.65 | 0.69 | 3.64% | 18.96 | 19.68 | 18.70 |
Nov 17, 2023 | 19.10 | 0.46 | 2.47% | 18.64 | 19.36 | 18.45 |
Nov 16, 2023 | 18.53 | -0.25 | -1.33% | 18.78 | 18.79 | 18.08 |
Nov 15, 2023 | 19.15 | 0.11 | 0.58% | 19.04 | 19.82 | 19.04 |
Nov 14, 2023 | 19.24 | 1.16 | 6.42% | 18.08 | 19.25 | 18.08 |
Nov 13, 2023 | 17.25 | 0.49 | 2.92% | 16.76 | 17.27 | 16.42 |
Nov 10, 2023 | 17.02 | -0.16 | -0.93% | 17.18 | 17.26 | 16.68 |
Sage Therapeutics, Inc. Events
Time (UTC) | Country | Event |
---|---|---|
Wednesday, February 14, 2024 | ||
Time (UTC) 13:30 | Country US
| Event Q4 2023 SAGE Therapeutics Inc Earnings Release Q4 2023 SAGE Therapeutics Inc Earnings ReleaseForecast -Previous - |
- Annual
- Quarterly
2022 | 2021 | 2020 | 2019 | 2018 | |
---|---|---|---|---|---|
Total revenue | 7.686 | 6.308 | 1114.2 | 6.868 | 90.273 |
Total Operating Expense | 554.675 | 467.217 | 517.974 | 714.992 | 483.511 |
Selling/General/Admin. Expenses, Total | 227.699 | 183.498 | 196.952 | 345.777 | 201.404 |
Research & Development | 326.163 | 283.166 | 292.714 | 368.815 | 282.107 |
Operating Income | -546.989 | -460.909 | 596.226 | -708.124 | -393.238 |
Interest Income (Expense), Net Non-Operating | 14.19 | 2.883 | 9.597 | 27.804 | 20.334 |
Other, Net | 0.015 | 0.134 | 0.25 | 0.082 | 0.022 |
Net Income Before Taxes | -532.784 | -457.892 | 606.073 | -680.238 | -372.882 |
Net Income After Taxes | -532.784 | -457.892 | 606.073 | -680.238 | -372.882 |
Net Income Before Extra. Items | -532.784 | -457.892 | 606.073 | -680.238 | -372.882 |
Net Income | -532.784 | -457.892 | 606.073 | -680.238 | -372.882 |
Income Available to Common Excl. Extra. Items | -532.784 | -457.892 | 606.073 | -680.238 | -372.882 |
Income Available to Common Incl. Extra. Items | -532.784 | -457.892 | 606.073 | -680.238 | -372.882 |
Diluted Net Income | -532.784 | -457.892 | 606.073 | -680.238 | -372.882 |
Diluted Weighted Average Shares | 59.3061 | 58.6702 | 53.0031 | 50.8338 | 46.1212 |
Diluted EPS Excluding Extraordinary Items | -8.98363 | -7.8045 | 11.4347 | -13.3816 | -8.08483 |
Diluted Normalized EPS | -8.98363 | -7.8045 | 11.9581 | -13.3816 | -8.08483 |
Total Extraordinary Items | |||||
Revenue | 7.686 | 6.308 | 1114.2 | 6.868 | 90.273 |
Cost of Revenue, Total | 0.813 | 0.553 | 0.565 | 0.4 | |
Gross Profit | 6.873 | 5.755 | 1113.64 | 6.468 | |
Unusual Expense (Income) | 0 | 0 | 27.743 |
Jun 2023 | Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | |
---|---|---|---|---|---|
Total revenue | 2.474 | 3.294 | 2.865 | 1.739 | 1.501 |
Revenue | 2.474 | 3.294 | 2.865 | 1.739 | 1.501 |
Cost of Revenue, Total | 0.205 | 0.23 | 0.143 | 0.184 | 0.2 |
Gross Profit | 2.269 | 3.064 | 2.722 | 1.555 | 1.301 |
Total Operating Expense | 172.931 | 158.764 | 156.767 | 143.219 | 129.908 |
Selling/General/Admin. Expenses, Total | 75.565 | 65.708 | 67.329 | 61.482 | 52.411 |
Research & Development | 97.161 | 92.826 | 89.295 | 81.553 | 77.297 |
Operating Income | -170.457 | -155.47 | -153.902 | -141.48 | -128.407 |
Interest Income (Expense), Net Non-Operating | 10.173 | 8.83 | 6.793 | 4.127 | 2.102 |
Other, Net | -0.041 | -0.188 | -0.037 | 0.03 | 0.045 |
Net Income Before Taxes | -160.325 | -146.828 | -147.146 | -137.323 | -126.26 |
Net Income After Taxes | -160.325 | -146.828 | -147.146 | -137.323 | -126.26 |
Net Income Before Extra. Items | -160.325 | -146.828 | -147.146 | -137.323 | -126.26 |
Net Income | -160.325 | -146.828 | -147.146 | -137.323 | -126.26 |
Income Available to Common Excl. Extra. Items | -160.325 | -146.828 | -147.146 | -137.323 | -126.26 |
Income Available to Common Incl. Extra. Items | -160.325 | -146.828 | -147.146 | -137.323 | -126.26 |
Diluted Net Income | -160.325 | -146.828 | -147.146 | -137.323 | -126.26 |
Diluted Weighted Average Shares | 59.7696 | 59.6741 | 59.4967 | 59.4281 | 59.2663 |
Diluted EPS Excluding Extraordinary Items | -2.68238 | -2.4605 | -2.47318 | -2.31074 | -2.13038 |
Dividends per Share - Common Stock Primary Issue | 0 | 0 | 0 | 0 | |
Diluted Normalized EPS | -2.68238 | -2.4605 | -2.47318 | -2.31074 | -2.13038 |
Unusual Expense (Income) | 0 |
- Annual
- Quarterly
2022 | 2021 | 2020 | 2019 | 2018 | |
---|---|---|---|---|---|
Total Current Assets | 1336.98 | 1800.64 | 2122.37 | 1035.09 | 944.695 |
Cash and Short Term Investments | 1272.49 | 1742.3 | 2099.55 | 1008.39 | 922.776 |
Cash & Equivalents | 162.7 | 294.233 | 1661.08 | 126.705 | 190.943 |
Short Term Investments | 1109.79 | 1448.06 | 438.467 | 881.688 | 731.833 |
Prepaid Expenses | 50.826 | 39.841 | 22.821 | 26.7 | 21.919 |
Total Assets | 1356.45 | 1825.29 | 2159.25 | 1084.15 | 952.705 |
Property/Plant/Equipment, Total - Net | 13.43 | 19.125 | 31.819 | 42.897 | 5.643 |
Property/Plant/Equipment, Total - Gross | 19.525 | 24.098 | 38.907 | 47.396 | 7.859 |
Accumulated Depreciation, Total | -6.095 | -4.973 | -7.088 | -4.499 | -2.216 |
Other Long Term Assets, Total | 6.039 | 5.52 | 5.057 | 6.16 | 2.367 |
Total Current Liabilities | 99.259 | 85.193 | 67.204 | 112.128 | 86.03 |
Accounts Payable | 18.95 | 10.45 | 3.691 | 15.266 | 34.036 |
Accrued Expenses | 37.572 | 26.703 | 23.931 | 33.202 | 19.875 |
Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities, Total | 42.737 | 48.04 | 39.582 | 63.66 | 32.119 |
Total Liabilities | 103.85 | 96.257 | 86.912 | 139.495 | 89.734 |
Total Long Term Debt | 0 | 0 | 0 | 0 | 0 |
Other Liabilities, Total | 4.591 | 11.064 | 19.708 | 27.367 | 3.704 |
Total Equity | 1252.6 | 1729.03 | 2072.33 | 944.655 | 862.971 |
Redeemable Preferred Stock | 0 | 0 | 0 | 0 | |
Common Stock | 0.006 | 0.006 | 0.006 | 0.005 | 0.005 |
Additional Paid-In Capital | 3291.37 | 3227.47 | 3109.81 | 2587.32 | 1827.02 |
Retained Earnings (Accumulated Deficit) | -2028.17 | -1495.39 | -1037.49 | -1643.57 | -963.329 |
Treasury Stock - Common | -0.4 | -0.4 | -0.4 | -0.4 | -0.211 |
Other Equity, Total | -10.206 | -2.66 | 0.415 | 1.295 | -0.515 |
Total Liabilities & Shareholders’ Equity | 1356.45 | 1825.29 | 2159.25 | 1084.15 | 952.705 |
Total Common Shares Outstanding | 59.5091 | 58.937 | 58.3084 | 51.8772 | 46.8883 |
Total Receivables, Net | 13.66 | 18.506 | |||
Accounts Receivable - Trade, Net | 13.66 | 18.506 |
Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | Sep 2022 | |
---|---|---|---|---|---|
Total Current Assets | 933.27 | 1064.03 | 1203.44 | 1336.98 | 1465.1 |
Cash and Short Term Investments | 876.052 | 1002.62 | 1129.58 | 1272.49 | 1393.64 |
Cash & Equivalents | 148.712 | 121.416 | 206.557 | 162.7 | 199.826 |
Short Term Investments | 727.34 | 881.2 | 923.028 | 1109.79 | 1193.81 |
Total Receivables, Net | 22.513 | 15.09 | 15.002 | 13.66 | 18.448 |
Accounts Receivable - Trade, Net | 22.513 | 15.09 | 15.002 | 13.66 | 18.448 |
Prepaid Expenses | 34.705 | 46.321 | 58.85 | 50.826 | 53.017 |
Total Assets | 949.663 | 1082.29 | 1220.69 | 1356.45 | 1486.07 |
Property/Plant/Equipment, Total - Net | 8.468 | 10.04 | 11.725 | 13.43 | 14.791 |
Property/Plant/Equipment, Total - Gross | 19.525 | ||||
Accumulated Depreciation, Total | -6.095 | ||||
Other Long Term Assets, Total | 7.925 | 8.221 | 5.524 | 6.039 | 6.178 |
Total Current Liabilities | 133.004 | 96.807 | 84.692 | 99.259 | 99.687 |
Accounts Payable | 11.136 | 9.283 | 12.263 | 18.95 | 7.077 |
Accrued Expenses | 45.985 | 27.789 | 18.369 | 37.572 | 28.299 |
Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities, Total | 75.883 | 59.735 | 54.06 | 42.737 | 64.311 |
Total Liabilities | 133.004 | 97.912 | 87.557 | 103.85 | 105.951 |
Total Long Term Debt | 0 | 0 | 0 | 0 | 0 |
Other Liabilities, Total | 0 | 1.105 | 2.865 | 4.591 | 6.264 |
Total Equity | 816.659 | 984.376 | 1133.13 | 1252.6 | 1380.12 |
Redeemable Preferred Stock | 0 | 0 | 0 | 0 | |
Common Stock | 0.006 | 0.006 | 0.006 | 0.006 | 0.006 |
Additional Paid-In Capital | 3357.74 | 3325.74 | 3313.61 | 3291.37 | 3276.42 |
Retained Earnings (Accumulated Deficit) | -2536.95 | -2335.32 | -2175 | -2028.17 | -1881.02 |
Treasury Stock - Common | -0.4 | -0.4 | -0.4 | -0.4 | -0.4 |
Other Equity, Total | -3.735 | -5.644 | -5.088 | -10.206 | -14.883 |
Total Liabilities & Shareholders’ Equity | 949.663 | 1082.29 | 1220.69 | 1356.45 | 1486.07 |
Total Common Shares Outstanding | 59.8839 | 59.796 | 59.762 | 59.5091 | 59.4937 |
- Annual
- Quarterly
2022 | 2021 | 2020 | 2019 | 2018 | |
---|---|---|---|---|---|
Net income/Starting Line | -532.784 | -457.892 | 606.073 | -680.238 | -372.882 |
Cash From Operating Activities | -460.036 | -378.182 | 664.28 | -528.706 | -260.671 |
Cash From Operating Activities | 1.122 | 4.182 | 2.63 | 2.283 | 1.143 |
Non-Cash Items | 65.955 | 94.034 | 95.306 | 142.591 | 91.856 |
Changes in Working Capital | 5.671 | -18.506 | -39.729 | 6.658 | 19.212 |
Cash From Investing Activities | 325.433 | -1002.45 | 442.684 | -143.156 | -512.461 |
Capital Expenditures | -0.937 | -0.372 | -0.345 | -5.751 | -2.86 |
Other Investing Cash Flow Items, Total | 326.37 | -1002.08 | 443.029 | -137.405 | -509.601 |
Cash From Financing Activities | 3.07 | 13.334 | 426.762 | 607.624 | 659.358 |
Financing Cash Flow Items | -0.043 | -1.385 | -2.503 | -1.244 | |
Issuance (Retirement) of Stock, Net | 3.113 | 14.719 | 426.762 | 610.127 | 660.602 |
Net Change in Cash | -131.533 | -1367.3 | 1533.73 | -64.238 | -113.774 |
Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | |
---|---|---|---|---|---|
Net income/Starting Line | -146.828 | -532.784 | -385.638 | -248.315 | -122.055 |
Cash From Operating Activities | -153.682 | -460.036 | -333.104 | -214.239 | -107.8 |
Cash From Operating Activities | 0.323 | 1.122 | 0.832 | 0.554 | 0.275 |
Non-Cash Items | 16.83 | 65.955 | 52.076 | 37.849 | 20.897 |
Changes in Working Capital | -24.007 | 5.671 | -0.374 | -4.327 | -6.917 |
Cash From Investing Activities | 194.867 | 325.433 | 235.656 | 124.704 | -9.558 |
Other Investing Cash Flow Items, Total | 195.092 | 326.37 | 236.311 | 124.995 | -9.389 |
Cash From Financing Activities | 2.672 | 3.07 | 3.041 | 1.812 | 1.799 |
Issuance (Retirement) of Stock, Net | 3.301 | 3.113 | 3.08 | 1.836 | 1.799 |
Net Change in Cash | 43.857 | -131.533 | -94.407 | -87.723 | -115.559 |
Capital Expenditures | -0.225 | -0.937 | -0.655 | -0.291 | -0.169 |
Financing Cash Flow Items | -0.629 | -0.043 | -0.039 | -0.024 |
Investor Name | Investor Type | Percent Outstanding | Shares Held | Shares change | Holdings Date | Turnover Rating |
---|---|---|---|---|---|---|
Fidelity Management & Research Company LLC | Investment Advisor | 14.6778 | 8789617 | 1706204 | 2023-06-30 | LOW |
Wellington Management Company, LLP | Investment Advisor/Hedge Fund | 10.6266 | 6363630 | 649207 | 2023-06-30 | LOW |
Biogen Inc | Corporation | 10.4226 | 6241473 | 0 | 2023-03-31 | HIGH |
The Vanguard Group, Inc. | Investment Advisor/Hedge Fund | 8.3815 | 5019202 | 53550 | 2023-06-30 | LOW |
BlackRock Institutional Trust Company, N.A. | Investment Advisor | 5.9624 | 3570538 | -11550 | 2023-06-30 | LOW |
Bellevue Asset Management AG | Investment Advisor | 5.2007 | 3114375 | 24375 | 2023-06-30 | LOW |
State Street Global Advisors (US) | Investment Advisor/Hedge Fund | 3.8393 | 2299140 | -435233 | 2023-06-30 | LOW |
Dimensional Fund Advisors, L.P. | Investment Advisor/Hedge Fund | 2.866 | 1716268 | 61568 | 2023-06-30 | LOW |
JP Morgan Asset Management | Investment Advisor | 1.857 | 1112064 | 291861 | 2023-06-30 | LOW |
Boxer Capital, L.L.C. | Hedge Fund | 1.8269 | 1094000 | 0 | 2023-06-30 | LOW |
Geode Capital Management, L.L.C. | Investment Advisor/Hedge Fund | 1.7827 | 1067545 | 27300 | 2023-06-30 | LOW |
T. Rowe Price Associates, Inc. | Investment Advisor | 1.7505 | 1048295 | -829697 | 2023-06-30 | LOW |
DWS Investment GmbH | Investment Advisor/Hedge Fund | 1.6699 | 1000000 | 300000 | 2023-06-30 | LOW |
Palo Alto Investors LP | Hedge Fund | 1.4353 | 859517 | 0 | 2023-06-30 | LOW |
Lord, Abbett & Co. LLC | Investment Advisor | 1.382 | 827577 | 637244 | 2023-06-30 | MED |
Marshall Wace LLP | Investment Advisor/Hedge Fund | 1.3335 | 798548 | -613381 | 2023-06-30 | HIGH |
Columbia Threadneedle Investments (US) | Investment Advisor/Hedge Fund | 1.0796 | 646495 | -228289 | 2023-06-30 | LOW |
Pictet Asset Management Ltd. | Investment Advisor/Hedge Fund | 1.0001 | 598918 | 592380 | 2023-06-30 | LOW |
Manulife Investment Management (North America) Limited | Investment Advisor | 0.9918 | 593938 | -30733 | 2023-06-30 | LOW |
JPMorgan Asset Management U.K. Limited | Investment Advisor/Hedge Fund | 0.864 | 517402 | 26317 | 2023-06-30 | LOW |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 20
- 100
- 500
- 1000
- 10000
Sage Therapeutic Company profile
About SAGE Therapeutics Inc
SAGE Therapeutics, Inc. is a biopharmaceutical company that is focused on developing and commercializing medicines with debilitating disorders of the brain. The Company's product, ZULRESSO (brexanolone) CIV injection, is for the treatment of postpartum depression (PPD), in adults. The Company's products also include ZULRESSO (Brexanolone) CIV Injection, Zuranolone (SAGE-217), SAGE-324 and SAGE-718. Its next advanced product candidate is SAGE-217, is an oral compound that is in Phase III clinical development in PPD and depressive disorder (MDD). Zuranolone is a neuroactive steroid that, like brexanolone, is a positive allosteric modulator of GABAA receptors, targeting both synaptic and extrasynaptic GABAA receptors. SAGE-324 is a GABAA receptor positive allosteric modulator intended for chronic oral dosing and conducting a placebo-controlled Phase II clinical trial evaluating the safety and efficacy of SAGE-324 in the treatment of essential tremor.
Financial summary
BRIEF: For the fiscal year ended 31 December 2021, SAGE Therapeutics Inc revenues decreased 99% to $6.3M. Net loss totaled $457.9M vs. income of $606.1M. Revenues reflect Collaboration revenue decrease from $1.11B to $0K, Product decrease of 6% to $6.3M. Net loss reflects Stock-based Compensation in R&D increase of 17% to $49.7M (expense), Stock-based Compensation in SGA increase of 6% to $54.9M (expense), Other income (expense).
Equity composition
Common Stock, $0.0001 Par, 07/14, auth. 120M shares,. 24,961,926 issd,. Insiders owns approx. 20.03%.
Industry: | Bio Therapeutic Drugs |
215 1st St
CAMBRIDGE
MASSACHUSETTS 02142
US
Income Statement
- Annual
- Quarterly
News

December RBA preview: no move expected at the final meeting of 2023
The RBA meets on Tuesday, 5th of December, 2023, at 2.30 PM (AEDT). We preview what to expect from this month’s decision.
14:47, 4 December 2023
CPI drops more than expected in Europe, Spain’s IBEX 35 looking to break pre-COVID highs
CPI drops more than expected in Europe, Spain’s IBEX 35 looking to break pre-COVID highs
12:39, 30 November 2023
Euro Zone CPI expected to continue dropping; economists warn about cutting too soon
EZ PI expected to drop further but speed of decline
08:16, 29 November 2023
A weaker Dollar drives gold higher
Gold prices have returned above $US2000 per ounce. We run through the factors driving gold and the commodity’s key technicals.
13:49, 28 November 2023
Q3 US Earnings Recap: Profits surprise to the upside, but outlook remains uncertain
US earnings for the third quarter were far better than expected. However, uncertainty about the outlook for company profits continues. We review the quarterly earnings and look ahead to what the markets expect from S&P 500 companies going forward.
13:20, 28 November 2023
RBNZ Preview: Rates expected to remain unchanged at final meeting of 2023
The RBNZ meets for the final time this year on Wednesday, 29th of November, 2023. We preview what to expect and how it could impact the New Zealand Dollar.
13:04, 28 November 2023
Crude prices slide on OPEC+ uncertainty
Crude prices have chopped sideways amid signs of turmoil within OPEC+. We look at the fundamentals of the oil market and the technical levels of WTI.
12:55, 28 November 2023People also watch
Still looking for a broker you can trust?
Join the 570.000+ traders worldwide that chose to trade with Capital.com